Hierarchical Framework for Nociplastic Pain: Implications for Psychedelic Trials

New Hierarchical Framework for Nociplastic Pain

A comprehensive hierarchical framework for nociplastic pain mechanisms was published on September 9, 2026, in a peer-reviewed review accessible via OpenAlex. The authors argue that nociplastic pain—pain arising from altered nociceptive processing without clear tissue damage or sensory lesion—cannot be fully explained by central sensitization alone. Instead, they propose a multi-level model encompassing spinal gain amplification, brainstem descending modulation, thalamocortical sensory gating, intrinsic network integration, corticolimbic affective-motivational processing, and perceptual inference. Neuroimmune signaling is highlighted as a cross-level modulator of excitability and plasticity.

This approach moves beyond traditional diagnostic labels, emphasizing the complexity and heterogeneity of chronic pain conditions such as fibromyalgia, chronic low back pain, and certain headache disorders. The framework encourages researchers to consider pain as an emergent property of interacting neural, immune, and psychological processes, rather than a single-pathway phenomenon.

Mechanistic Insights and the Role of Biomarkers

The hierarchical model offers mechanistic insights that are directly relevant to the design of clinical trials, including those investigating psychedelics as potential interventions for chronic pain. By mapping pain persistence to specific neurobiological and affective-motivational processes, the framework generates testable predictions about which patients may respond to particular treatments.

• Biomarker-driven stratification: The framework advocates for the use of pre-treatment sensory, neurophysiological, neuroimaging, molecular, affective, and behavioral profiles to stratify patients in clinical trials.
• Falsifiable predictions: The model suggests that linking these profiles to treatment response can yield falsifiable hypotheses, enabling more rigorous evaluation of both pharmacological and non-pharmacological interventions.
• Non-selective pharmacological agents: The authors specifically note that non-selective agents—including psychedelics—could be used to perturb multiple nodes in the pain processing hierarchy, providing a rationale for their inclusion in mechanism-focused studies.

One non-obvious implication is that psychedelic trials targeting chronic pain may benefit from enrolling biomarker-defined subgroups, rather than heterogeneous populations defined only by symptom reports or diagnostic criteria. This could increase the likelihood of detecting true treatment effects and reduce the risk of false negatives in early-phase studies.

Policy and Research Implications for Psychedelic Trials

The hierarchical framework has significant implications for policy, trial design, and research funding in the emerging field of psychedelic-assisted pain management. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly emphasize the importance of mechanism-based endpoints and patient stratification in clinical trial protocols.

• Stratified trial designs: Sponsors of psychedelic trials may need to incorporate biomarker-based inclusion criteria, such as functional MRI (fMRI) signatures or neuroimmune markers, into their protocols to satisfy regulatory expectations for precision medicine approaches.
• Mechanism-based endpoints: The framework supports the use of mechanistic endpoints—such as changes in thalamocortical connectivity or neuroimmune activity—alongside traditional pain scales, potentially accelerating regulatory review and payer acceptance.
• Funding priorities: Public and private funders may prioritize studies that explicitly test the hierarchical model's predictions, particularly those that integrate neuroimaging, molecular, and behavioral data to identify treatment-responsive subgroups.

For example, a trial investigating psilocybin for fibromyalgia might pre-screen participants using quantitative sensory testing and fMRI to identify individuals with pronounced thalamocortical dysregulation, hypothesizing that these patients are more likely to benefit from serotonergic modulation.

Risks, Unknowns, and Cautions

While the hierarchical framework offers a promising roadmap for advancing pain research, several risks and unknowns remain. The complexity of the model may complicate trial logistics and increase costs, as multi-modal biomarker assessments require specialized equipment and expertise. There is also a risk of overfitting—designing trials that are too narrowly tailored to specific mechanistic hypotheses, potentially missing broader treatment effects.

Moreover, the framework's applicability to psychedelic interventions is still largely theoretical. Most psychedelic trials to date have not incorporated comprehensive biomarker-driven stratification, and the predictive validity of proposed biomarkers remains to be established. Regulatory acceptance of novel endpoints, such as changes in network integration or neuroimmune signaling, is not guaranteed and may require extensive validation in multi-site studies.

Finally, the review cautions against discarding traditional clinical endpoints, emphasizing that mechanistic insights should complement, not replace, patient-centered outcomes such as pain relief and functional improvement.

Looking Ahead: Opportunities for Innovation

The publication of a hierarchical framework for nociplastic pain marks a pivotal step toward mechanism-informed clinical research, with direct implications for psychedelic trials targeting chronic pain. By enabling more precise patient stratification and mechanistic hypothesis testing, the model may accelerate the development of effective, personalized interventions. However, realizing this potential will require close collaboration among neuroscientists, clinicians, trialists, and regulators, as well as sustained investment in biomarker discovery and validation.

As psychedelic research moves beyond psychiatric indications into the realm of chronic pain, the adoption of such frameworks could distinguish successful programs from those that fail to demonstrate efficacy in heterogeneous patient populations. The coming years will reveal whether this approach can deliver on its promise to transform pain management and improve outcomes for millions living with nociplastic pain.

Written by Dr. Alex Morgan, PhD (Neuroscience), Psychedelic Research Journal Editor.How we research: This article was reviewed by Dr. Alex Morgan on 2026-09-10. Primary source: OpenAlex W7212067755.